Open Orphan, Bahamas Petroleum Co and Chris Bailey on Unilever, Ocado, Just Eat & Johnson Matthey
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Open Orphan, Bahamas Petroleum Co and Chris Bailey on Unilever, Ocado, Just Eat & Johnson Matthey
Cathal Friel, Executive Chairman of Open Orphan (ORPH) talks about the major contract its signed with a leading vaccine developer and one of the top pharmaceutical companies in the world.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.
Simon Potter, Chief Executive Officer of Bahamas Petroleum Co (BPC) explains the synergies and opportunities behind the recommended all-share merger of them and Columbus Energy Resources.
The Bahamas Petroleum Company was formed to invest in an offshore oil exploration programme in licence areas covering approximately 16,000 sq km (4 million acres) in the territorial waters and maritime Exclusive Economic Zone (EEZ) of The Bahamas. The Group holds 100% interests through wholly owned subsidiaries in five Exploration Licences granted by the Government of the Commonwealth of The Bahamas, and has applications for an additional 5 licences.
(Interview starts at 11 minutes 4 seconds)
Chris Bailey founder of Financial Orbit covers news from the following companies:
(Interview starts at 23 minutes 22 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.